Table 2:
Variables | CBDEP group (n=19) | P-Value | Placebo group (n=17) | P-Value | Mean difference | 95% CI | P-Value | ||
---|---|---|---|---|---|---|---|---|---|
Baseline | 8 weeks | Baseline | 8 weeks | ||||||
Renal function | |||||||||
BUN (mg/dL) | 14.29±4.09 | 13.34±3.72 | 0.193 | 12.82±3.56 | 13.67±5.14 | 0.274 | −1.63 | −3.16 to−0.95 | 0.037* |
Cr (mg/dL) | 0.86±0.19 | 0.87±0.17 | 0.616 | 0.87±0.19 | 0.87±0.20 | 0.858 | 0.006 | −0.34 to 0.45 | 0.786 |
Liver function | |||||||||
Total protein | |||||||||
(g/dL) | 7.83±0.31 | 7.70±0.30 | 0.012* | 8.07±0.48 | 7.98±0.30 | 0.005* | 0.02 | −0.11 to 0.15 | 0.749 |
Albumin (g/dL) | 4.09±0.19 | 4.11±0.17 | 0.943 | 4.23±0.21 | 4.09±0.23 | <0.001* | 0.13 | 0.06 to 0.19 | <0.001* |
Globulin (g/dL) | 3.74±0.31 | 3.59±0.29 | 0.001* | 3.84±0.46 | 3.81±0.47 | 0.695 | −0.13 | −0.24 to−0.03 | 0.011* |
Total bilirubin (mg/dL) | 0.59±0.13 | 0.65±0.18 | 0.060 | 0.59±0.14 | 0.71±0.19 | 0.001* | −0.05 | −0.12 to 0.03 | 0.209 |
Direct bilirubin (mg/dL) | 0.10±0.05 | 0.10±0.05 | 0.973 | 0.09±0.05 | 0.11±0.05 | 0.085 | −0.02 | −0.05 to 0.003 | 0.088 |
Indirect bilirubin (mg/dL) | 0.49±0.11 | 0.56±0.15 | 0.018* | 0.51±0.12 | 0.59±0.15 | 0.002* | −0.02 | −0.85 to 0.04 | 0.492 |
ALP (U/L) | 77.81±30.52 | 66.27±18.46 | <0.001* | 73.74±18.49 | 67.46±18.85 | 0.013* | −4.2 | −9.57 to 1.17 | 0.126 |
AST (U/L) | 27.73±6.94 | 26.26±7.47 | 0.110 | 27.7±6.91 | 24.74±5.28 | 0.002* | 1.51 | −0.53 to 3.54 | 0.147 |
ALT (U/L) | 20.04±7.94 | 16.34±7.26 | <0.001* | 19.84±12.60 | 18.05±9.90 | 0.074 | −1.88 | −3.97 to 0.21 | 0.078 |
A/G ratio | 1.10±0.12 | 1.15±0.11 | 0.026* | 1.12±0.15 | 1.09±0.15 | 0.073 | 0.08 | 0.03 to 0.13 | 0.002* |
Data are presented as mean±standard deviation, *P<0.05, CBDEP, cannabidiol-enriched cannabis extraction product; CI, confidence interval; BUN, blood urea nitrogen; Cr, creatinine; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; A/G ratio, albumin/globulin ratio.